An Educational Resource I'm Writing for Patients, to Learn About Topics in Sleep Medicine and Neurology in an Informal-but-Professional Manner
Showing posts with label Dementia. Show all posts
Showing posts with label Dementia. Show all posts
Monday, January 6, 2014
Memantine (Namenda) for Lewy Body Dementia
Thing you should know #1: Memantine, also known by its trade name Namenda, works by blocking a receptor called NMDA (stands for N-methyl-D-aspartate). It is thought that in dementia, like Alzheimer's, over-excitation of this receptor (usually by a specific chemical glutamate which is the most important excitatory chemical in the human brain)--over-excitation of this receptor can actually lead to cell death and be a part of the process that causes dementia (neurodegeneration) to progress further. Blocking this receptor is supposed to selectively block the excitatory pathway while allowing the normal day-to-day functions of the cell to continue unabated. And the initial studies on dementia & this medication were really only done with the Alzheimer's kind of dementia.
Thing you should know #2: Namenda is only FDA approved for moderate to severe Alzheimer's disease.
Thing you should know #3: If we in the medical world waited for the FDA to catch up by approval to all that is being treated in certain ways in Medicine, we would push back the way Medicine is practiced 40 years... at least.
Thing you should know #4: There are many types of dementia. You hear about Alzheimer's all the time because it is the most common form of one category of dementia and because the media really highlights this form of dementia. But.... B12 deficiency can cause a dementia; thyroid dysfunction and depression and Obstructive Sleep Apnea can mimic dementia; large strokes or many smaller strokes can cause dementia ....on and on. And of the specific category of dementias known as NEURODEGENERATIVE DEMENTIAS, Alzheimer's is just one of them among others like Lewy Body Dementia, Frontotemporal Dementia, Semantic Dementia, Non-fluent Aphasia Dementia.....and so-on.
So, this quick article summary essentially suggests what many neurologists have already been recommending: We should be using this medication that decreases over-excitation leading to brain cell death in dementia, more broadly that just in Alzheimer's type. And, although this study summary above doesn't mention it, we should also be using the classic medication used for Alzheimer's, Aricept (donepezil) more broadly as well among the other dementias.
This study from August 2010 The Lancet Neurology, showed that over 24 weeks (half a year) of the study's duration, the patients had statistically significant improvements (over placebo), actual improvements, in overall cognition and in behavioral measures as well (since many patients understandably have behavioral issues when aspects of the brain lose their path, but other conflicting aspects remain fully capable).
In this study, complete data was a available for 159 patients, which is a pretty robust number.
But, to me, it really just confirms that we shouldn't be waiting to place our loved ones on medications, such as this, until studies are built to prove what should work based on our neurologic understanding and what we see in clinical practice.... as long as the treatment does not break our fundamental oath of "Do no harm." That being said, even that truth has shades of grey. I'm perfectly comfortable given someone a touch of stomach-nausea (harm) if I think I can delay some memory problems/behavioral problems just a bit longer, especially if that means you/your family can stay in your/their home a few months or years longer before having to transition to expense home nursing or to a nursing home.
Labels:
Dementia
Monday, June 3, 2013
Falling is Death. How can we prevent it?
This post is
meant for older individuals, those over the age of 65, or their
family/caretaker.
By the way, any products I note below, are just because they fit
what I thought worked.
I get absolutely no money from anybody for any of this.
I can't tell you
how many times I talk about falling concerns in my patients; patients with
stroke-related weakness, Parkinson's disease, MS, dementia in all its forms.... The increased fall risk is actually a combination of things usually: age-related fragility, poor eyesight,
dizziness, neuropathy, bad knees & slow arms at catching oneself.
But I think most
people don't realize what happens when an older person falls. Not only do they
bruise themselves thoroughly, get poorly-healing abrasions, pull muscles & tendons, torque their back, and get subdural hematomas crushing their brain, and
fracture their wrists, but they quite often get hip fractures.
Hip fractures are surprisingly more common than people realize.
87% to 96% of hip fracture patients are 65 years of age or older.
Hip fractures after a fall, while more common in women due to greater prevalences of osteopenia and osteoporosis, are slightly more mortal in men.
Half the people who fall and have ANY injury, never return home and end up spending their remaining days in a nursing home. The hip-injury group is even higher.
87% to 96% of hip fracture patients are 65 years of age or older.
Hip fractures after a fall, while more common in women due to greater prevalences of osteopenia and osteoporosis, are slightly more mortal in men.
Half the people who fall and have ANY injury, never return home and end up spending their remaining days in a nursing home. The hip-injury group is even higher.
But let's talk
about mortality:
-After a hip
fracture, the 1 year mortality is 27%
-After a hip
fracture, the 3.7 year mortality (length of follow up in one study that followed 428
patients) is 80% (This is a 3-fold higher chance of dying than the general
population)
-The most common
cause of death was circulatory diseases
Another very large
study, which compiles a bunch of other studies (called a meta-analysis) from
2010 compiled the information from hip fracture mortality studies (22 cohort
studies in women and 17 in men), age 50 and older with hip fractures.
Survival curves were compared between them and a group of people of the same
age and gender who did NOT have a hip fracture.
The hip fracture
group had a 5- to 8-fold increased
risk for all-cause mortality during the first 3 months after hip fracture.
Excess annual mortality persists over time for both women and men.
OK. So if you or your loved one are somewhere between 3 and 8 times more likely to die from the complications of a hip fracture, then how can we prevent that?
Most falls occur at home, not out in public, so securing the home is paramount.
Here is my advice:
1. Keep a diary of any new symptoms on a monthly calendar, not a piece of scratch paper. A calendar gives a more visual connection to symptoms, often easier to correlate to any recent medication changes or other general health changes. It's amazing how subtle things can lead to hip fractures: I saw a woman three months ago who had nausea from a recent simple medication change lead to decreased appetite & thirst which lead to increased dizziness which lead to a fall and hip fracture. She is still in a rehabilitation center instead of comfortably in her own home.
2. Install grab bars in the shower and next to the toilet. If there is even a remote chance of falls, you can bring this up with your primary care physician, and they will gladly consult a home health company who will come out and evaluate your fall risk and install grab bars, paid for by Medicare and most private insurance companies.
3. Use non-slip rubber mats in the bathtub and shower. They are cheap and easy to install. The grittier the better, but you may want to install them in the front half of the shower/bathtub (where most people stand to shower anyway) so that they won't be too rough on the patient's underside should they take a bath later.
4. Keep your home well lit at night (when you are NOT going to bed).
5. Once going to bed, do NOT keep a bedside lamp or overhead light on all night long. Keeping lights on like this all night long only adds to poor sleep quality and sleepiness during the day.
I also don't even care for bright night lights like the one pictured just below:
I also don't even care for bright night lights like the one pictured just below:
--I like the fact that it senses when it's dark, so automatically comes on, but I don't like the fact that it is "megabrite" without a direction down onto the carpet, which means it's going to shine all over the room as a source of light pollution which can hurt night vision and interfere with sleep quality since our brain responds strongly to such light pollution (our circadian rhythm).
I recommend the following night light; one that has these elements:
-- motion sensor which is not on any longer than it needs to be, just enough to help walking to and from the restroom
-- the ability to tilt the direction of light down to the ground instead of diffusely into the room more broadly
-- LED lights which will last and don't require frequent bulb changes
6. Remove thick or shaggy decorative rugs and replace with no rugs or at least very thin rugs heavy-weight rugs less likely to be caught be a misstep or get tangled up in a misplaced foot. Double-sided tape should also be used to secure the corners and lengths/widths. One patient of mine took regular-ole' duck tape and folded it over for cheap double-sided tape.
7. Eliminate clutter from the room: paperwork, Tupperware boxes, electrical cords.
8. Remove knee-high clutter: coffee tables, tea tables, trunks & chests, extra chairs, awkwardly-protruding lamp stands.
9. Don't store commonly used things too high or too low. Too high causes people to do silly things like stand on chairs or balance precariously on tiptoes. Too low causes people to topple over while reaching down, or toppling over when trying to lift a cumbersome box, or get dizzy when they stand back up and topple over at that point.
10. Wear sturdy shoes with non-skid soles
11. Wear non-skid slipper socks at night if you have wooden floors or wooden floors in the kitchen, often visited for a sip of water during the night. You can see below, they are not expensive at all.
12. Have a ground line phone at each level, or at the very least, a cradle with an attached cord near the master bed where the cellphone rests each night. In case there is a fall, the person can (yikes!) possibly drag themselves to the phone to pull the cord and get to the phone to call for help, so they might not languish on the floor in the same spot with a broken hip overnight, or for a day or longer depending on their situation.
13. Use liquid soap from a secured dispenser mounted on the wall or in a secured cradle. I have had patients fall as they bend over to pick up the dropped soap or even stepping on the dropped soap.
14. Keep a large amount of space between pieces of furniture so that the person's gait can remain wide instead of getting unnaturally narrowed.
15. Steps: They should be well-lit with down-casting night lights that automatically come on when it gets dark, and even though it looks gaudy, should have bright tape on the edges, so that the edges can be easily visualized when the person is going down AND up the stairs.
16. Lastly, make sure the cane(s) being used around the house are approved by and discussed with a physical therapist. EVERY doctor will be willing to have you see a physical therapist if there is a potential fall risk and especially if you ask. And the physical therapist will be more than willing to help you pick out and learn to wield the best cane for EVERY situation. I see people with the wrong cane (and often dangerous) for them all the time.
Thursday, May 16, 2013
Hydration in the Elderly.... the Coffee-Water Rule
I see so many older adults with headaches, dizziness when they stand, hypertension, chronic dry mouth & dry eyes, memory complaints...
I could discuss direct and indirect mechanisms by which chronic dehydration leads to worsening of these issues, but that's not the point here. It's just a truth, a known relationship.
I'm often surprised that we in the medical community don't bother our patients enough about the importance of hydration and am often surprised at how often I see my patients internally rolling their eyes when I bring it up, as if they don't see where their lack of hydration, chronically usually, can actually increase their risk for stroke. Or they yawn at such advice because they don't feel thirsty and assume they are hydrating "enough." This little entry is not about how much is right for each person, because there are numerous factors involved, but I do see a LARGE number of my patients walking around with chronic dehydration. It's endemic it seems.
I have a rule for my older adults (and frankly middle-aged adults should follow it too), and I got the idea from my mother, where it was known in my youth as the Grape-Juice-Water Rule.
I love grape juice. Even now, when I'm out with friends at a party, if there's the option of a beer or grape juice, I'll be the one sipping on the purple stuff. But grape juice is expensive. And growing up, my mother couldn't afford to supply me with an endless supply of grape juice when I came in from outside sweaty and thirsty. So she gave me a choice: She could either start buying as much of the purple powder stuff (grape drink) or I could follow her Grape-Juice-Water-Rule
So, I have modified the rule for my adults who need to work on their hydration.
I could discuss direct and indirect mechanisms by which chronic dehydration leads to worsening of these issues, but that's not the point here. It's just a truth, a known relationship.
I'm often surprised that we in the medical community don't bother our patients enough about the importance of hydration and am often surprised at how often I see my patients internally rolling their eyes when I bring it up, as if they don't see where their lack of hydration, chronically usually, can actually increase their risk for stroke. Or they yawn at such advice because they don't feel thirsty and assume they are hydrating "enough." This little entry is not about how much is right for each person, because there are numerous factors involved, but I do see a LARGE number of my patients walking around with chronic dehydration. It's endemic it seems.
I have a rule for my older adults (and frankly middle-aged adults should follow it too), and I got the idea from my mother, where it was known in my youth as the Grape-Juice-Water Rule.
I love grape juice. Even now, when I'm out with friends at a party, if there's the option of a beer or grape juice, I'll be the one sipping on the purple stuff. But grape juice is expensive. And growing up, my mother couldn't afford to supply me with an endless supply of grape juice when I came in from outside sweaty and thirsty. So she gave me a choice: She could either start buying as much of the purple powder stuff (grape drink) or I could follow her Grape-Juice-Water-Rule
THE GRAPE-JUICE-WATER RULE:
When I come in from outside thirsty, I have to first drink a full glass of tap water BEFORE I am allowed to drink an equal-amount glass of grape juice. And then after that I can alternate between water and grape juice, a half-glass at a time. And if she saw that I wasn't seeming to follow such a rule, I would just start seeing the powdered grape drink in the fridge instead of actual juice.So, I have modified the rule for my adults who need to work on their hydration.
Dr. Kirk's COFFEE-WATER-HYDRATION RULE:
You can drink your 8 oz cup of coffee in the morning, BUT you have to FOLLOW it with two 8 oz glasses of water afterward, which both keeps you more hydrated (especially since coffee actually makes people lose more water, as a diuretic), and the water coming afterward helps reduce the teeth staining that comes from wonderful coffee.
AND
I tried to make the glass of water look more exciting.
Labels:
Caffeine,
Dementia,
Migraines and Headaches
Tuesday, April 16, 2013
At home, twice-a-week, customized exercise helps independence in dementia patients
What is this study?
Nothing really new, but it's a well-designed, "clean" study.
It confirms what we've all already known about humans: We weren't designed to be still and it's why long-haul truck driver health is notoriously precarious, people get deep vein thrombosis (DVT) after long plane and car trips, and why disabled elderly men and women are more likely to die after a fall-induced hip fracture (17% of women die within the year)....among other examples of why a sedentary lifestyle diminishes the quality of our lives.
And this detrimental stillness only worsens in its deleterious effects the older we are, and the effects on thinking are profound not only in people who retire and stop keeping their minds active, but are even worse among patients with dementia who are now working with less mental reserve than they used to.
So this study from the Journal of the American Medical Association (JAMA) looked at patients with the actual Alzheimer's form of dementia (keep in mind there are other forms of dementia as well).
It was trying to tell us whether or not exercise actually helps reduce the rate of further decline in the patient's ability to self-participate in their own activities of daily living (ADLs).
It looked at 210 patients, all over the age of 65.
They were followed for 1 year.
It divided them into three groups:
1. Twice-a-week hour-long group exercise
2. Twice-a-week hour-long tailored/customized home exercise
3. Usual community-available care
A physical therapist evaluated them using a 0 to 126 point scale, with a higher number meaning they were more functional/needed less help. Mobility itself was also measured with a formal test (Short Physical Performance Battery).
At one year:
ALL patients had some deterioration in physical functioning based on the above point system.
BUT:
1. Twice-a-week group exercisers only lost 10.3 points on their 0-126 scale assessment
2. Twice-a-week home exercisers lost only 7.1 points on their 0-126 scale assessment
3. The patients who just took advantage to whatever community infrastructure is already in place dropped the most, losing 14.4 points on their 0-126 scale assessment
So, the people who exercised twice a week with a tailored/customized home exercise program did the best, with less progression of their inability to independently participate in their own activities of daily living.
Interestingly, the yearly cost for the people who just took advantage of what was already available in the community was $35,121 (the most expensive), but the group who got the customized home exercise program cost the least at $25,112/year. To me that's a big savings for better care and most importantly a better life for the patients.
I mailed a copy of this study to each of the insurance companies we work with and addressed it to their Medical Director.
Here's a longer version of the above if you would like to read it:
-------------------------------------------------------------------------------------------------------
Workout
Helps with ADL in Alzheimer's
Published: April 2013
An exercise program for people with Alzheimer's disease
helped them cope with activities of daily living, without increasing health and
social care costs, researchers reported.
In a randomized, controlled trial, supervised exercise,
whether at home or at a day care center, slowed physical deterioration, according
to Kaisu Pitkälä, MD, PhD, of the University of Helsinki in Finland, and
colleagues.
And the costs for patients in the exercise programs were
similar or lower than those associated with a control program of usual
community care, Pitkälä and colleagues reported online in JAMA Internal
Medicine.
The two main characteristics of Alzheimer's disease are
cognitive decline and functional deterioration, including progressively greater
need for help in daily activities, the researchers noted.
But although there is extensive research on exercise in
older people, there are "surprisingly few rigorous studies" looking
at exercise in people with dementia, they commented.
To help fill the gap, they enrolled 210 people with
Alzheimer's disease (ages 65 and up) who could walk independently and were
living at home under the care of a spouse. Participants had to meet one of the
following conditions:
- At least one fall during the past year
- Decreased walking speed
- Unintentional weight loss
They were randomly assigned to one of three groups for a
year of study – group sessions twice weekly with about an hour of exercise,
tailored home-based exercise for an hour twice a week, and a control group
getting usual community care.
Physical functioning was assessed using the Functional
Independence Measure, a scale that runs from 0 to 126, with higher scores
indicating less need for help in daily living. Mobility was measured with the
Short Physical Performance Battery.
The researchers retrieved data on the use of health and
social services from both government registers and medical records.
After a year, they found, all patients had deteriorating
physical function, but those in the exercise programs had slower declines. For
instance, the decline on the functional independence measure after a year was
7.1 points for those in the home exercise group, 10.3 points for those taking
group exercise, and 14.4 points for those in the control group.
The difference between the home exercise group and the
control group reached statistical significance (P=0.004), but those
taking group exercise did not differ significantly from the controls.
But in a mixed effects model, the decline was significantly
slower in the exercise groups both at 6 months (P=0.003), and at a year
(P=0.015).
There was no significant effect on changes in mobility.
On average, the yearly cost for health and social services
in the control group was $34,121 compared with $22,066 for those taking group
exercise and $25,112 for those in the home exercise cohort.
In a bootstrap-type analysis of covariance, the researchers
reported, the difference from controls was significant (P=0.03) for
those taking group exercise, but nonsignificant, although lower on average, for
those exercising at home.
The study is "very difficult to criticize,"
commented Paul Schulz, MD, of the University of Texas Health Science Center in
Houston.
"It really was randomized, it really was controlled,
and it was partly blinded," Schultz told MedPage Today.
An important implication, he said, may be a knock-on effect
on cognition. Research in other areas has suggested that exercise improves
cognition by reducing other risk factors for dementia, such as heart disease
and high blood pressure.
"Getting the Alzheimer's patients to exercise is not
only going to improve their activities of daily living, which was the purpose
of the study, but it may also help their cognitive status," he said.
Pitkälä and colleagues noted that the findings should be
generalized with caution, because volunteers were selected, motivated, and white.
Also, the study was relatively small, and nearly a quarter of the
patient-caregiver pairs dropped out, owing to death or other reasons.
Nevertheless, the findings are "a welcome addition to
(the) scanty literature" on ways to preserve physical abilities in people
with Alzheimer's disease, commented A. Mark Clarfield, MD, and Tzvi Dwolatzky,
MD, both of Ben-Gurion University of the Negev in Beersheba, Israel.
But they cautioned in their accompanying commentary that
participants volunteered for the study, so that the "strength of the
conclusions may have been weakened by the healthy volunteer effect."
In addition, the differences between groups in expected
declines over the study period are statistically significant but "not very
clinically significant, in our minds."
On the positive side, they concluded that the study suggests
the "good news" of a benefit from exercise may apply even to people
"well into the process of decline."
Labels:
Dementia
Tuesday, July 17, 2012
IVIG stops the progression of Alzheimers!!! Or just gives you a stroke?
This just came out in the news today, and I've already received a few calls from some of my patients and their family about it, so I think I should address it.
First, some basics.
The actual constellation of factors which lead to the development of Alzheimer's disease (which, by the way, is just one of a dozen or more causes of the family of neurodegenerative dementias) is hotly debated. BUT, there is a lot of research around the role of a person's immune system, specifically, that people who develop Alzheimer's may be having a problem with their immune system accidentally attacking certain cells or proteins in the brain or causing damaging inflammation in parts of the brain.
As a very broad explanation, we believe that in Alzheimer's Disease, certain proteins in the cells of the brain start misfolding and building up (instead of being dissolved as they should) until they get in the way of normal cellular function... and until the cell eventually dies as a result, slowly adding up over time to affect thinking and behavior. The initial cells to be involved classically affect memory first and later other parts of the brain, sometimes rapidly, and sometimes very slowly.
Current treatment involves trying to keep the cells that are currently living as healthy for as long as possible, or help the chemicals they use to communicate between them (like acetylcholine), stick around longer by stopping the natural enzymes which break this messenger chemical down. The current treatment do NOT really affect the underlying problem/cause and, overall, may add years at best to independent living... but are by no means perfect, and do not add decades to normal living and definitely do not stop the disease.
Most patients with Alzheimer's Disease have notable progression every 3 to 6 months on average.
The treatment they are discussing, IVIG (Intravenous immunoglobulin), is a high-viscosity (thick) infusion (made from donated blood) given in a monitored setting (like a dedicated infusion suite or a hospital) over an hour or so. It is a treatment designed to halt the progression of an autoimmune process (your body attacking some aspect of itself). Because IVIG is thick, it can rarely cause an artery to clot and lead to a heart attack, renal failure, or stroke. Ouch! Normally it causes just a rash as a side effect fortunately. Currently, it costs somebody (insurance or the patient) around $10,000 per treatment (which goes to the pharmaceutical company, not your doctor).
Now, in this study, there is documented cessation of Alzheimer's progression. That is wonderful, and I love that it paves the way for more research in this area. In fact, another study with over 300 patients of somewhat similar design is nearing completion as well.
Over the 3 years that these patients were treated with IVIG, they had NO PROGRESSION OF THEIR ALZHEIMER'S DISEASE.
Wonderful, right?!.... Well, this is an example of how media hype can mislead us.
A closer look:
-Only 4 patients received the full 36 months (3 years) of IVIG treatment every 2 weeks, and only these 4 had complete halting of the disease. One of these 4 had a stroke as a complication.
-There were only 24 total patients enrolled in the treatment (patients with mild-to-moderate dementia). That's not a lot, BUT they all did have reduced progression rates of their decline in thinking compared to those who received sham/fake medication; these latter patients continuing to worse as expected.
-Those that switch from the placebo(sham/fake) treatment to the IVIG treatment, starting doing better as well, in regards to the stabilization of the disease progression.
So, this is very promising, but there were not a lot of patients in the study as a whole, one did have a stroke as a likely treatment complication (which is just as bad as Alzheimer's in my book), they had to get a monitored IV treatment every 2 to 4 weeks, and the cost or copay would be quite high.
I plan to wait on more evidence that it's worth it on all fronts before I set a patient up with this treatment.
If you want to read a more detailed report, see below line:
--------------------------------------------------------------------------------------------------------------------------
This study was published as an abstract and presented at a conference (Alzheimer's Association International Conference).
These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
Study abstract title: Relkin N, et al "Three-year follow-up on the IVIG for Alzheimer's phase II study" AAIC 2012; Abstract P3-381.
First, some basics.
The actual constellation of factors which lead to the development of Alzheimer's disease (which, by the way, is just one of a dozen or more causes of the family of neurodegenerative dementias) is hotly debated. BUT, there is a lot of research around the role of a person's immune system, specifically, that people who develop Alzheimer's may be having a problem with their immune system accidentally attacking certain cells or proteins in the brain or causing damaging inflammation in parts of the brain.
As a very broad explanation, we believe that in Alzheimer's Disease, certain proteins in the cells of the brain start misfolding and building up (instead of being dissolved as they should) until they get in the way of normal cellular function... and until the cell eventually dies as a result, slowly adding up over time to affect thinking and behavior. The initial cells to be involved classically affect memory first and later other parts of the brain, sometimes rapidly, and sometimes very slowly.
Current treatment involves trying to keep the cells that are currently living as healthy for as long as possible, or help the chemicals they use to communicate between them (like acetylcholine), stick around longer by stopping the natural enzymes which break this messenger chemical down. The current treatment do NOT really affect the underlying problem/cause and, overall, may add years at best to independent living... but are by no means perfect, and do not add decades to normal living and definitely do not stop the disease.
Most patients with Alzheimer's Disease have notable progression every 3 to 6 months on average.
The treatment they are discussing, IVIG (Intravenous immunoglobulin), is a high-viscosity (thick) infusion (made from donated blood) given in a monitored setting (like a dedicated infusion suite or a hospital) over an hour or so. It is a treatment designed to halt the progression of an autoimmune process (your body attacking some aspect of itself). Because IVIG is thick, it can rarely cause an artery to clot and lead to a heart attack, renal failure, or stroke. Ouch! Normally it causes just a rash as a side effect fortunately. Currently, it costs somebody (insurance or the patient) around $10,000 per treatment (which goes to the pharmaceutical company, not your doctor).
Now, in this study, there is documented cessation of Alzheimer's progression. That is wonderful, and I love that it paves the way for more research in this area. In fact, another study with over 300 patients of somewhat similar design is nearing completion as well.
Over the 3 years that these patients were treated with IVIG, they had NO PROGRESSION OF THEIR ALZHEIMER'S DISEASE.
Wonderful, right?!.... Well, this is an example of how media hype can mislead us.
A closer look:
-Only 4 patients received the full 36 months (3 years) of IVIG treatment every 2 weeks, and only these 4 had complete halting of the disease. One of these 4 had a stroke as a complication.
-There were only 24 total patients enrolled in the treatment (patients with mild-to-moderate dementia). That's not a lot, BUT they all did have reduced progression rates of their decline in thinking compared to those who received sham/fake medication; these latter patients continuing to worse as expected.
-Those that switch from the placebo(sham/fake) treatment to the IVIG treatment, starting doing better as well, in regards to the stabilization of the disease progression.
So, this is very promising, but there were not a lot of patients in the study as a whole, one did have a stroke as a likely treatment complication (which is just as bad as Alzheimer's in my book), they had to get a monitored IV treatment every 2 to 4 weeks, and the cost or copay would be quite high.
I plan to wait on more evidence that it's worth it on all fronts before I set a patient up with this treatment.
If you want to read a more detailed report, see below line:
--------------------------------------------------------------------------------------------------------------------------
IVIG Stops Alzheimer's in Its Tracks
Published: July 17, 2012
Three years of treatment with intravenous immunoglobulin (IVIG, GammaGard) prevented further cognitive decline in patients with Alzheimer's disease, according to a small study presented here.
As measured by multiple standard instruments -- the Alzheimer's Disease Assessment Scale (ADAS-Cog), the Clinical Global Impression of Change (CGIC) index, the Neuropsychiatric Inventory, and others -- the four patients who received the full 36 months of treatment at 0.4 g/kg every 2 weeks showed no decline in scores, reported Norman Relkin, MD, of Weill Cornell Medical College in New York City.
At a press briefing prior to his formal presentation at the Alzheimer's Association International Conference, Relkin said the treatment was "generally well-tolerated" but did cause some adverse effects. None were unusual and most were relatively mild infusion-related reactions such as rashes.
Some were more serious, though. These included a stroke in one patient, presumably related to the viscosity of IVIG, which is known to increase risk of ischemic events.
A phase III study with 390 patients is already nearing completion, with results expected by mid-2013, he said.
The rationale for IVIG in Alzheimer's disease is that it contains antibodies against beta amyloid proteins and it also modulates immune function to reduce inflammation, Relkin explained.
The current report covered a second open-label extension of an earlier placebo-controlled, double-blind trial that initially lasted 6 months, involving 24 patients with mild to moderate Alzheimer's disease (baseline Mini-Mental State Examination scores of 14 to 26).
As a phase II study, it tested multiple doses and schedules. Besides the four patients assigned to 0.4 g/kg every 2 weeks, four patients each received 0.2 g/kg every 2 weeks, 0.4 g/kg every 4 weeks, and 0.8 g/kg every 4 weeks. Eight patients received placebo.
Results from the randomized phase indicated that, in pooled data for all patients assigned to IVIG, the treatment outperformed placebo in the primary outcome measures of ADAS-Cog and CGIC, as well as in other cognitive assessments.
Participants were allowed to receive an additional year of open-label treatment with IVIG. With continued favorable results -- including inhibition of brain atrophy as well as cognitive protection -- a second 18-month extension was offered, with 21 patients accepting. For this second extension, all patients received 0.4 g/kg every 2 weeks, since that appeared to be the most effective regimen in the previous data.
These included all 16 initially receiving IVIG and five of the placebo group.
The second extension essentially confirmed the earlier findings and showed that the benefits last 3 years, Relkin said.
Patients initially assigned to placebo showed continued decline in cognitive function, but there was "a bend in the curve" when they were switched to IVIG, Relkin said, reflecting a slowing in decline.
Pooled data for the 16 patients in the original IVIG groups showed a significant protective effect relative to the initial placebo group. Mean values for ADAS-Cog and CGIC scores indicated some loss of cognitive ability, but it was relatively small.
But the highlight finding, Relkin said, was that 3-year ADAS-Cog and CGIC scores in the four patients who received 0.4 g/kg every 2 weeks throughout the study were the same as at baseline.
Untreated Alzheimer's disease patients in his clinic nearly always show measurable decline in 3 to 6 months, he said.
"If we have a patient who goes out to 18 or 24 months without changing, usually we begin to doubt that they have Alzheimer's disease. If we have two patients like that in our practice, we begin to doubt our own diagnostic prowess," he said.
"To have four patients... all of whom are effectively unchanged after 3 years, is a remarkable result."
Relkin started his press conference talk with the customary presentation disclaimer that he would be discussing the off-label use of an approved product, but then gave it an unusual emphasis.
He noted that the findings were from very few patients, and therefore very preliminary. "It's a very important point because this agent is in limited supply, and the indications for which it is approved, some of them represent disorders in which patients can only survive by getting this particular product. So we don't want to bankrupt the available supplies."
Labels:
Dementia
Subscribe to:
Posts (Atom)






